A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation

被引：0
|
作者：
Midori Nakagaki
Michael Barras
Cameron Curley
Jason P. Butler
Glen A. Kennedy
机构：
[1] Royal Brisbane and Women’s Hospital,Pharmacy Department, Level 1 Ned Hanlon Building
[2] The University of Queensland,Bone Marrow Transplant Unit, Level 5 Joyce Tweddell Building
[3] Royal Brisbane and Women’s Hospital,undefined
来源：
Supportive Care in Cancer | 2017年 / 25卷
关键词：
Stem cell transplantation; Antiemetics; Ondansetron; Palonosetron; Olanzapine; Nausea and vomiting;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：607 / 613
页数：6
相关论文
共 50 条
  • [1] A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation
    Nakagaki, Midori
    Barras, Michael
    Curley, Cameron
    Butler, Jason P.
    Kennedy, Glen A.
    SUPPORTIVE CARE IN CANCER, 2017, 25 (02) : 607 - 613
  • [2] The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
    Navari, Rudolph M.
    Nagy, Cindy K.
    Gray, Sarah E.
    SUPPORTIVE CARE IN CANCER, 2013, 21 (06) : 1655 - 1663
  • [3] The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
    Rudolph M. Navari
    Cindy K. Nagy
    Sarah E. Gray
    Supportive Care in Cancer, 2013, 21 : 1655 - 1663
  • [4] ONDANSETRON VERSUS GRANISETRON IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING - RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL
    GEBBIA, V
    CANNATA, G
    TESTA, A
    CURTO, G
    VALENZA, R
    CIPOLLA, C
    LATTERI, MA
    GEBBIA, N
    CANCER, 1994, 74 (07) : 1945 - 1952
  • [5] Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer
    Fujiwara, Satoe
    Terai, Yoshito
    Tsunetoh, Satoshi
    Sasaki, Hiroshi
    Kanemura, Masanori
    Ohmichi, Masahide
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2015, 26 (04) : 311 - 319
  • [6] Multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer
    Kim, Jin Soo
    Kim, Ji Yeon
    Lee, Sang-Jeon
    Park, Dong Kook
    Namgung, Hwan
    Kim, Chang Nam
    Choi, Won Jun
    Baek, Moo Jun
    ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2014, 87 (01) : 9 - 13
  • [7] ONDANSETRON VERSUS METOCLOPRAMIDE IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING - A METAANALYSIS
    RUSTHOVEN, J
    OBRIEN, BJ
    ROCCHI, A
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1992, 1 (04) : 443 - 450
  • [8] Comparison of netupitant/palonosetron with 5-hydroxytryptamine-3 receptor antagonist in preventing of chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation
    Zhang, Hang
    Zeng, Qiang
    Dong, Tian
    Chen, Xinchuan
    Kuang, Pu
    Li, Jian
    Wu, Qiuhui
    Liu, Ting
    Niu, Ting
    Liu, Zhigang
    Ji, Jie
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [9] Daily Palonosetron Is Superior to Ondansetron in the Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting in Patients With Acute Myelogenous Leukemia
    Mattiuzzi, Gloria N.
    Cortes, Jorge E.
    Blamble, Deborah A.
    Bekele, Nebiyou
    Xiao, Lianchun
    Cabanillas, Maria
    Borthakur, Gautam
    Brien, Susan O.
    Kantarjian, Hagop
    CANCER, 2010, 116 (24) : 5659 - 5666
  • [10] A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation
    Bubalo, Joseph S.
    Radke, Jennifer L.
    Bensch, Kenneth G.
    Chen, Andy, I
    Misra, Shikha
    Maziarz, Richard T.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (02) : 304 - 312
12345